RxDoctor Payments Data

Gerald Harder, MD

Internal Medicine · Southlake, TXNPI 1457375396

Payments from drug & device makers

$1,250in general payments, 2019–2025

Across 64 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$323
  • Dexcom, Inc.$184
  • Edwards Lifesciences$142
  • AbbVie$129
  • Boehringer Ingelheim$74
  • Biohaven Pharmaceuticals, Inc.$44
  • plus $355 from 15 others

What the payments were for

  • Food & beverage$1,250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,250 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$225,810
Medicare patients
487
Services billed
3,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$113,242
JardianceEmpagliflozin71$107,797
MounjaroTirzepatide77$86,220
EliquisApixaban64$75,265
XareltoRivaroxaban24$30,918
FarxigaDapagliflozin Propanediol18$23,365
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,256
SymbicortBudesonide/Formoterol Fumarate22$7,003
SynthroidLevothyroxine Sodium83$6,249
Wixela InhubFluticasone Propion/Salmeterol20$6,229
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,160
Vivelle-DotEstradiol20$4,090
Atorvastatin Calcium482$4,016
Levothyroxine Sodium383$3,981
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$113,24293 claims
Boehringer IngelheimJardiance$74$107,79771 claims
Lilly USA, LLCMounjaro$27$86,22077 claims
PfizerEliquis$28$75,26564 claims
GSKTrelegy Ellipta, Arnuity Ellipta$323$14,89022 claims
AbbVieSynthroid$129$6,24983 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Southlake

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →